VCAM1 and metabolic dysfunction-associated steatotic liver disease: To test this hypothesis, we employed an anti-VCAM-1 nanobody labeled with technetium-99m (99mTc-cAbVCAM1-5, currently undergoing clinical evaluation for atherosclerosis imaging) in various preclinical models of NAFLD.